NASDAQ: RNAZ - TransCode Therapeutics, Inc.

Yield per half year: -98.17%
Dividend yield: 0.00%
Sector: Healthcare

Share chart TransCode Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.

more details
In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-07-08
ISIN US89357L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.transcodetherapeutics.com
Цена ао 0.59
Change price per day: 0% (0.41)
Change price per week: +5.67% (0.388)
Change price per month: -47.29% (0.7778)
Change price per 3 month: -87.8% (3.36)
Change price per half year: -98.17% (22.407)
Change price per year: -18.81% (0.505)
Change price per 3 year: -85.61% (2.85)
Change price per year to date: -89.35% (3.85)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.8291 9
P/E 0 0
EV/EBITDA 0.0506 10
Total: 4.88

Efficiency

Title Value Grade
ROA, % -358.75 0
ROE, % -1130.3 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0238 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 3832.92 10
Yield EPS, % 88301.02 10
Total: 8
More

Institutions Volume Share, %
Sabby Management, LLC 250309 1
UBS Group AG 146530 0.58
Tang Capital Management, LLC 84010 0.33
Private Capital Management LLC 80704 0.32
Virtu Financial LLC 31347 0.12
HRT Financial LP 16358 0.07
Two Sigma Investments, LP 16153 0.06
Warberg Asset Management LLC 10000 0.04
Tower Research Capital LLC (TRC) 5340 0.02
Royal Bank of Canada 22 0



Head Job title Payment Year of birth
Mr. Thomas A. Fitzgerald M.B.A. Interim CEO, CFO, President, VP of Administration & Director 358.14k 1952 (73 years)
Dr. Zdravka Medarova Ph.D. Co-Founder & Chief Scientific Officer N/A 1975 (50 years)
Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor & Member of Scientific Advisory Board N/A 1962 (63 years)
Ms. Susan Duggan M.B.A., R.N. Senior Vice President of Operations N/A
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board 102.5k 1959 (66 years)
Dr. Daniel R. Vlock M.D. Chief Medical Officer 1952 (73 years)

Address: United States, Boston. MA, 6 Liberty Square - open in Google maps, open in Yandex maps
Website: https://www.transcodetherapeutics.com